Catalyst
Slingshot members are tracking this event:
Aimmune (AIMT) Announces Phase 2 ARC002 Data Evaluating AR101 in Treatment of Peanut Allergy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 06, 2016
Related Projects
- Comparing Aimmune's (AIMT) Peanut Allergy Medication AR101 to DBV Technology's (DBVT) Viaskin Peanut As They Race for FDA Approval AIMT, DBVT Executed On: Jun 23, 2016 at 11:00 AM EDT
Related Keywords
Arc002 Phase 2 Trial, Ar101, Peanut Allergy
